PharmEnable is a biopharmaceutical company utilizing AI to discover effective small-molecule medicines for disease targets that are inaccessible to antibodies. With our proprietary AI-enabled drug discovery platform, chemSEEK, we explore new chemical spaces and discover novel small molecules with antibody-like specificity and selectivity. We are developing a pipeline of wholly owned therapeutics with initial focus on oncology and neurology. We also engage in drug discovery partnerships across a range of disease areas where accessing the target poses a significant challenge. PharmEnable is based in Cambridge, UK, and is a spinoff of the University of Cambridge. Discover how we are reimagining small molecule therapeutics through AI at pharmenabletx.com and connect with us on LinkedIn.
| Website | http://www.pharmenabletx.com |
| Employees | 13 (12 on RocketReach) |
| Technologies |
JavaScript
,
HTML
,
PHP
+15 more
(view full list)
|
| Industry | Biotechnology Research, Biotechnology, Science and Engineering, Life Science, Medical, Health Care, Pharmaceutical |
| Keywords | Drug Target Identification, Ai Drug Discovery, New Chemical Entities, Lead Optimization, Drug Discovery Platform, Molecular Modeling, Biopharmaceutical Research, Biotechnology, Pharmaceutical Development, Pharmaceutical Ai, Precision Medicine, Drug Design Software, Computational Drug Design, Innovative Medicines, In Silico Drug Discovery, Machine Learning Therapeutics, Cheminformatics |
| Competitors | Amgen, Boehringer Ingelheim, Elekta, Intellia Therapeutics, Inc., Fate Therapeutics Inc, Cardurion Pharmaceuticals, Horizon Discovery, Alchemab Therapeutics Ltd, ChemBridge Corporation, Moleculera Labs +37 more (view full list) |
Looking for a particular PharmEnable employee's phone or email?
Natalia Mateu is the Founder and CSO of PharmEnable.
12 people are employed at PharmEnable.